The decision to go it alone in marketing the rare disease drug Vyvgart in the US looks a wise one for argenx N.V., with the Belgian-Dutch biotech off to a strong start following the therapy's approval for generalized myasthenia gravis (gMG).
The US Food and Drug Administration gave the green light to Vyvgart (efgartigimod), Argenx’s first approved product, on 17 December...







